OptiBiotix Health Plc

Consumer study of LPLDL® in Cholbiome® products

SPONSORED ARTICLE

By Elric Langton | 1 February 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces its wholly-owned subsidiary, ProBiotix Health Ltd, has carried out a consumer study (n=46) on its CholBiome® products.

CholBiome®X3 and CholBiome®BP are ProBiotix’s patented and proprietary formulations developed to reduce cardiovascular disease risk using the probiotic strain LPLDL®, on which a third double-blind, randomised, placebo-controlled human clinical study was recently published documenting a statistically significant effect of LPLDL® in reducing total cholesterol, LDL-cholesterol and APO-B: Third human clinical trial LPLDL® in hypercholesterolemic adults - ScienceDirect. (RNS: 18 January 2022)

Powder Monkey offers our readers a 10% discount on their first purchase using the discount code SCC10.

Human studies are essential in providing a scientific, clinical, and statistical evidence base for user intervention in a controlled environment. First, however, it’s necessary to check these findings reflect the real-world use of products that are best assessed by receiving structured feedback from consumers. 

The consumer study was carried out by contacting customers who purchased CholBiome® products from the website

The results of the survey are shown below:-

1. 96% of consumers who had taken CholBiome®X3 and measured their total cholesterol levels reported that their levels had reduced. Of these:-

   1. 17% reported reductions in total cholesterol of >30%

   2. 50% reported reductions in total cholesterol of between 16-30%

   3. 29% reported reductions in total cholesterol of between 1-15%

2. 88% of consumers stated that their LDL-cholesterol (bad cholesterol) had been reduced (with 8% not knowing their LDL cholesterol levels).

3. This level of reduction was sustained, with 93% of users who took the product for more than one year reporting reduced levels of total and LDL cholesterol.

4. No consumers taking CholBiome®X3 reported any side effects or tolerance issues.

The P-Values are of particular interest, statistically speaking because the chance of these reductions is calculated as 1/100 or 1/800 depending on the P-value you chose.

To understand the significance of the data, it is worth comparing it to well-known statin products. As you can see from the slide below, LPLDL® is a superior product to Lipitor and Bempedoic Acid; both are pharmaceutical drugs.

The potential is clear. There can be no doubting the statistical body of evidence that indicates LPLDL® works exceptionally well and is superior to drugs with well-established sales. Furthermore, each report and peer review highlights LPLDL® to pharmaceutical suitors. As a result, I believe there is growing interest from pharmaceutical corporations. In addition, LPLDL® has GRAS and FDA approval, which means it can be added to food that is considered safe, further strengthening the marketing attractiveness of LPLDL®.

ProBiotix is already manufacturing and supplies agreement with USA based partner USPharma Lab a family-owned and operated business with facilities in the US, India and China, and employing more than 600 people globally.

The USA probiotic market is estimated to be worth $7.1 billion per annum. The US is one of the largest and fastest-growing probiotic markets globally, with supplements alone accounting for $2.06 billion sales, with a projected 55% growth to $3.3 billion by 2021.

Pfizer’s cholesterol-lowering drug Lipitor sales were $1.9 billion in 2019. Although lipitor’s patent expired in 2011, it is still the most prescribed anti-cholesterol medication globally. In 15 years (1996 – 2011) of market dominance, Lipitor raked in $125 billion in sales, becoming the best-selling drug in the pharmaceutical industry's history.

Esperion's Bempedoic Acid drug, otherwise known as Nexletol, used to treat hypertension, helped the company beat analysts forecasts due to increasing prescriptions sales. The company reported net product revenue in the quarter comprised of Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) of $10.9M, up from $4.8M in the prior-year period.

Some investors have been eager for OptiBiotix to be bolder less shy when promoting their products. As a result, LPLDL® has been reserved for science-related journals and health publications, not the more mainstream publication where the footfall is likely to drive sales. This is now changing, and perhaps Stephen O’Hara’s strategy has been to build the body of evidence so it is overwhelming it cannot be ignored.

For example, Us long-term investors will be well aware of science, peer reviews, clinical study, and consumer studies. But, of course, this all takes time for the corporate strategy to play out. Grass and FDA approval sets LPLDL® apart from a large body of probiotics that do not have the science supporting evidence, let alone GRAS or FDA approval, which should prove invaluable.

Listen to this circa 6 mins radio interview (excerpt) with Dr Ranj Singh today, covering the recent great results is achieving. LPLDL® mentioned a few times and direction to Optibiotix website nicely at the end to boot.

Hopefully, LPLDL® will be more widely available if proper publicity can be put in place, other than peeps like other investors who swear by CholBiome. I have been using CholBiome x3 for two years and found it highly effective, so much so my GP assumed I had adopted his Avrostatin prescription. Unfortunately, I had not explained what I had been using. Sadly, as good as the NHS is, it seems slow to adapt to new products. Perhaps one day, we will see an NHS serviced much as AlfaSigma does to the Italian NHS.

Mikkel Hvid-Hansen, Commercial Director of Probiotics, commented: “The combination of scientific, clinical, and consumer studies on LPLDL®, and formulations like the CholBiome® product range provide a growing body of evidence for its safe and effective use in reducing biomarkers of cardiovascular risk like total cholesterol, LDL cholesterol, and Apolipoprotein B. We now have five scientific publications, three human studies, two consumer studies and numerous positive product reviews which gives us confidence in the use of LPLDL®. We now feel we have evidence broadly comparable to Phase I/II pharmaceutical studies which we can use to open up further partnering or licensing opportunities for use of LPLDL® as an OTC product by itself or in combination with existing treatments (e.g. statins), or as a drug biotherapeutic in markets outside the USA.”

Powder Monkey offers our readers a 10% discount on their first purchase using the discount code SCC10.